Bioceltix Balance Sheet

Financials in millions PLN. Fiscal year is January - December.

Millions PLN. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	20.04	9.31	4.12	6.05
Cash & Short-Term Investments	20.04	9.31	4.12	6.05
Cash Growth	20.09%	125.98%	-31.96%	-
Accounts Receivable	0	0	0	-
Other Receivables	2.72	1.88	0.23	0.44
Receivables	2.73	1.88	0.23	0.44
Inventory	0.02	0.01	-	-
Prepaid Expenses	0.04	0.01	0.01	0.01
Other Current Assets	27.49	0	1.67	0.01
Total Current Assets	50.31	11.21	6.02	6.51
Property, Plant & Equipment	1.37	1.48	1.46	1.53
Long-Term Deferred Tax Assets	0.04	0.04	0.03	0.02
Other Long-Term Assets	0.29	-	0.14	0.14
Total Assets	52.01	12.74	7.65	8.2
Accounts Payable	3.47	1.21	0.96	0.29
Accrued Expenses	0.52	0.44	0.34	0.19
Current Portion of Leases	0.15	0.1	0.12	0.38
Current Income Taxes Payable	0.28	0.36	0.27	0.12
Current Unearned Revenue	0.01	0.03	0.56	0.93
Total Current Liabilities	6.98	2.14	2.25	1.91
Long-Term Leases	0.06	0.08	0.18	0.15
Long-Term Unearned Revenue	0.01	-	0.03	0.06
Long-Term Deferred Tax Liabilities	0.06	0.04	0.04	0.07
Total Liabilities	7.12	2.27	2.5	2.2
Common Stock	0.49	0.41	0.34	0.33
Additional Paid-In Capital	52.83	23.8	14.44	15.14
Retained Earnings	-8.43	-13.74	-13.99	-9.47
Comprensive Income & Other	-	-	4.36	-
Shareholders' Equity	44.89	10.47	5.15	6
Total Liabilities & Equity	52.01	12.74	7.65	8.2
Total Debt	0.21	0.18	0.29	0.53
Net Cash (Debt)	19.83	9.14	3.83	5.52
Net Cash Growth	20.50%	138.76%	-30.74%	-
Net Cash Per Share	4.79	2.33	1.15	1.75
Filing Date Shares Outstanding	4.92	4.13	3.98	3.29
Total Common Shares Outstanding	4.92	4.13	3.43	3.29
Working Capital	43.33	9.07	3.78	4.61
Book Value Per Share	9.12	2.53	1.50	1.82
Tangible Book Value	44.89	10.47	5.15	6
Tangible Book Value Per Share	9.12	2.53	1.50	1.82
Buildings	0.33	0.33	0.33	0.33
Machinery	0.27	0.27	0.24	0.25

Source: S&P Capital IQ. Standard template. Financial Sources.